GlassScriptPhysician profile
David D Schmitt
NPI 1346237906
$804.24
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $122 · 2022: $248 · 2023: $22.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $208.49 | 2019-2022 | |
| Portola Pharmaceuticals, LLC | $182.55 | 2019-2020 | |
| Organogenesis INC. | $125.00 | 2022 | |
| Merck Sharp & Dohme LLC | $60.86 | 2019-2023 | Recarbrio, Dificid |
| Ethicon US, LLC | $46.63 | 2019 | |
| Lemaitre Vascular, INC. | $45.47 | 2019 | |
| Mallinckrodt Enterprises LLC | $28.21 | 2019 | |
| Integra Lifesciences Corporation | $26.61 | 2019-2020 | |
| Tela Bio, INC. | $24.13 | 2020 | |
| Shire North American Group INC | $17.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.02 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.97 | 2019 | |
| Osiris Therapeutics INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schmitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.